- Home
- RDVT vs ALT Comparison
RDVT vs ALT Comparison
Compare RDVT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- ALT
- Stock Information
- Founded
- RDVT 2017
- ALT 1997
- Country
- RDVT United States
- ALT United States
- Employees
- RDVT N/A
- ALT N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- ALT Health Care
- Exchange
- RDVT Nasdaq
- ALT Nasdaq
- Market Cap
- RDVT 538.6M
- ALT 472.3M
- IPO Year
- RDVT N/A
- ALT N/A
- Fundamental
- Price
- RDVT $36.72
- ALT $4.55
- Analyst Decision
- RDVT
- ALT Strong Buy
- Analyst Count
- RDVT 0
- ALT 8
- Target Price
- RDVT N/A
- ALT $21.00
- AVG Volume (30 Days)
- RDVT 79.2K
- ALT 2.2M
- Earning Date
- RDVT 05-07-2025
- ALT 05-08-2025
- Dividend Yield
- RDVT 0.81%
- ALT N/A
- EPS Growth
- RDVT N/A
- ALT N/A
- EPS
- RDVT 0.50
- ALT N/A
- Revenue
- RDVT $75,189,000.00
- ALT $20,000.00
- Revenue This Year
- RDVT $15.93
- ALT N/A
- Revenue Next Year
- RDVT $13.85
- ALT N/A
- P/E Ratio
- RDVT $73.63
- ALT N/A
- Revenue Growth
- RDVT 24.89
- ALT N/A
- 52 Week Low
- RDVT $16.56
- ALT $3.55
- 52 Week High
- RDVT $43.44
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- RDVT 47.11
- ALT 43.21
- Support Level
- RDVT $36.16
- ALT $4.32
- Resistance Level
- RDVT $37.93
- ALT $4.75
- Average True Range (ATR)
- RDVT 2.26
- ALT 0.38
- MACD
- RDVT 0.02
- ALT 0.05
- Stochastic Oscillator
- RDVT 64.23
- ALT 63.22
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.